Brief: United Laboratories International Application For Clinical Trial Of Ubt251 Approved By NMPA
29/08/2023 15:38
Aug 29 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* APPLICATION FOR CLINICAL TRIAL OF CLASS 1 INNOVATIVE NEW
DRUG
UBT251 INJECTION APPROVED BY CHINA NMPA
Source text for Eikon: ID:nHKS7zRSj8
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million